BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld MedTech
Home
» Deals roundup: Novartis buys majority stake in Alcon for $23.3B
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Deals roundup: Novartis buys majority stake in Alcon for $23.3B
Aug. 27, 2010
By
Amanda Pedersen
No Comments
Novartis (Basel, Switzerland) and Nestlé (Vevey, Switzerland) say they have completed the purchase and sale of nearly 156 million shares of Alcon (Huenenberg, Switzerland) for $28.3 billion in cash. (Medical Device Daily)
BioWorld MedTech